DNER and leukemia: In general, inhibition of BET proteins has shown efficacy for both hematological cancers including leukemia, lymphoma, multiple myeloma and for solid tumors such as NMC (Nut midline carcinoma), prostate cancer and ovarian cancer [10, 15, 25–29].